Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

…, TM Maher, FJ Martinez, M Molina-Molina… - American Journal of …, 2022 - atsjournals.org
Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

…, M Kreuter, DJ Lederer, M Molina-Molina… - The lancet Respiratory …, 2020 - thelancet.com
Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …

Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study

…, G Margaritopoulos, M Molina-Molina… - American journal of …, 2020 - atsjournals.org
Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …

Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis

…, M Ng, R Braybrooke, M Molina-Molina… - American journal of …, 2020 - atsjournals.org
Rationale: Idiopathic pulmonary fibrosis (IPF) is a complex lung disease characterized by
scarring of the lung that is believed to result from an atypical response to injury of the …

[HTML][HTML] Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a …

…, N Villalba, J Marcoval, A Iriarte, M Molina-Molina… - Medicine, 2017 - journals.lww.com
Cohort studies of large series of patients with sarcoidosis over a long period of time are scarce.
The aim of this study is to report a 40-year clinical experience of a large series of patients …

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

X Li, M Molina-Molina, A Abdul-Hafez… - … of Physiology-Lung …, 2008 - journals.physiology.org
Earlier work from this laboratory showed that local generation of angiotensin (ANG) II is
required for the pathogenesis of experimental pulmonary fibrosis and that ANG peptides are …

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

…, S Herrera, J Moises, M Molina-Molina… - The Lancet respiratory …, 2019 - thelancet.com
Background A hallmark of idiopathic pulmonary fibrosis is the excess accumulation of
extracellular matrix in the lungs. Degradation of extracellular matrix generates free-circulating …

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

…, G Jenkins, TM Maher, M Molina-Molina… - The Lancet …, 2018 - thelancet.com
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and typically fatal lung
disease characterised by subpleural fibrosis, subepithelial fibroblast foci, and microscopic …

Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials

…, JMC Martinez, EF Fabrellas, V Leiro, M Molina-Molina… - Jama, 2023 - jamanetwork.com
Importance There is a major need for effective, well-tolerated treatments for idiopathic
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor …

Angiotensin-TGF-β1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages

…, J Kyong Kim, X Li, M Molina-Molina - Current pharmaceutical …, 2007 - ingentaconnect.com
Angiotensin II (ANGII) has been identified as a proapoptotic and profibrotic factor in
experimental lung fibrosis models, and patients with the ID/DD polymorphism of ANG converting …